Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVITA Medical, Inc.RCEL · Entity 5905 | CFO | June 12, 2026 | August 24, 2026 |
| SOLENO THERAPEUTICS INCCAPN · Entity 46432 | Director | April 19, 2017 | April 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVITA Medical, Inc.
Report date June 12, 2026 · Filed August 24, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 152,927 |
Reported balance
After 2026-06-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 2,000 · Balance 152,927 F1: The original Form 4, filed on June 12, 2026, inadvertently used transaction code 'A' instead of transaction code 'P'. This amendment corrects the transaction code. F2: Includes unvested RSUs |
Filing footnotes · ownership attribution and instrument terms
F1: The original Form 4, filed on June 12, 2026, inadvertently used transaction code 'A' instead of transaction code 'P'. This amendment corrects the transaction code.
F2: Includes unvested RSUs
SOLENO THERAPEUTICS INC
Report date April 19, 2017 · Filed April 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2027-04-19 | Direct | 354,945 |
Reported balance
After 2017-04-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-19 · Grant · Acquired 354,945 · Balance 354,945 F1: One fourth (1/4) of the shares subject to the Option shall vest immediately on the Vesting Commencement Date (which is April 19, 2017), and one forty-eighth (1/48) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to Participant continuing to be a Service Provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4) of the shares subject to the Option shall vest immediately on the Vesting Commencement Date (which is April 19, 2017), and one forty-eighth (1/48) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to Participant continuing to be a Service Provider through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OPIANT PHARMACEUTICALS, INC.
Report date March 02, 2023 · Filed March 03, 2023
Section 16 reporting ended · disclosed 2023-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-03-02 · Disposition to issuer · Disposed 22,512 · Balance 11,736 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Row 2 · 2023-03-02 · Disposition to issuer · Disposed 11,736 · Balance 0 F2: Disposed of pursuant to the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 11,736 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. Row 3 · 2023-03-02 · Grant · Acquired 2,000 · Balance 2,000 F3: 2,000 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer. Row 4 · 2023-03-02 · Disposition to issuer · Disposed 2,000 · Balance 0 F4: Disposed of pursuant the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.61 · Expires 2029-01-02 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-02 · Disposition to issuer · Disposed 33,000 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2031-01-26 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-02 · Disposition to issuer · Disposed 10,750 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2030-01-07 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-02 · Disposition to issuer · Disposed 8,250 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
F2: Disposed of pursuant to the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 11,736 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
F3: 2,000 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer.
F4: Disposed of pursuant the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement.
F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 12, 2026 20:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 2,000 | $3.97 | $7,940.00 |
DisclosureSEC source: 0001193125-26-269544 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,927 F1 · balance_after: Includes unvested RSUs Read SEC document |
| June 12, 2026 Filed Aug 24, 2026 21:00 UTC Amendment | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 2,000 | $3.97 | $7,940.00 |
DisclosureSEC source: 0001193125-26-363747 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,927 F1 · kind: The original Form 4, filed on June 12, 2026, inadvertently used transaction code 'A' instead of transaction code 'P'. This amendment corrects the transaction code. F2 · balance_after: Includes unvested RSUs Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 20:39 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 5,000 | $3.05 | $15,257.50 |
DisclosureSEC source: 0001193125-26-251588 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,927 F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period). F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period). F2 · balance_after: Includes unvested RSUs Read SEC document |
| May 20, 2026 Filed May 20, 2026 20:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 2,000 | $4.26 | $8,520.00 |
DisclosureSEC source: 0001193125-26-232686 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,927 F1 · balance_after: Includes unvested RSUs Read SEC document |
| May 19, 2026 Filed May 19, 2026 20:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 2,000 | $4.24 | $8,480.00 |
DisclosureSEC source: 0001193125-26-230874 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,927 F1 · balance_after: Includes unvested RSUs Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 20:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,800 | $4.78 | $8,604.00 |
DisclosureSEC source: 0001193125-26-102263 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,927 F1 · balance_after: Includes unvested RSUs Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 3,000 | $4.15 | $12,450.00 |
DisclosureSEC source: 0001193125-26-064111 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,127 F1 · balance_after: Includes unvested RSUs. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:38 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 155,510 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001193125-26-059552 · ownership.xml · derivative · entry 2 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,510 Underlying: Common Stock · 155,510 shares Expires 2036-02-18 F3 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date of February 18, 2026. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:38 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 105,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-059552 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,127 F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments beginning on the date 12 months following the grant date of February 18, 2026. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| August 26, 2025 Filed Aug 26, 2025 20:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 2,000 | $4.52 | $9,040.00 |
DisclosureSEC source: 0000950170-25-111467 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,657 Read SEC document |
| August 12, 2025 Filed Aug 12, 2025 20:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 2,000 | $4.81 | $9,620.00 |
DisclosureSEC source: 0000950170-25-107387 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,657 Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 20:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 1,923 | $4.78 | $9,186.17 |
DisclosureSEC source: 0000950170-25-080304 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,657 F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2024 and ended on May 31, 2025 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 30, 2025 (the purchase date of the offering period). F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2024 and ended on May 31, 2025 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 30, 2025 (the purchase date of the offering period). Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 21:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $9.90 | $9,900.00 |
DisclosureSEC source: 0000950170-25-024204 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,734 Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 21:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $10.25 | $10,250.00 |
DisclosureSEC source: 0000950170-25-023233 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,734 Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $8.73 | $0.00 |
DisclosureSEC source: 0000950170-25-007794 · ownership.xml · derivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-01-21 F1 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date. Read SEC document |
| December 05, 2024 Filed Dec 5, 2024 22:00 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 500 | $12.40 | $6,200.00 |
DisclosureSEC source: 0000950170-24-133748 · ownership.xml · nonDerivative · entry 3 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,734 Read SEC document |
| December 05, 2024 Filed Dec 5, 2024 22:00 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 475 | $12.53 | $5,951.75 |
DisclosureSEC source: 0000950170-24-133748 · ownership.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,234 Read SEC document |
| November 29, 2024 Filed Dec 5, 2024 22:00 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 785 | $7.83 | $6,146.55 |
DisclosureSEC source: 0000950170-24-133748 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,759 F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period which began on June 1, 2024 and which ended on November 30, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 3, 2024 (the purchase date of the offering period). Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 20:27 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 2,240 | $8.17 | $18,297.44 |
DisclosureSEC source: 0000950170-24-068006 · ownership.xml · nonDerivative · entry 3 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,974 F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 31, 2024 (the purchase date of the offering period). F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 31, 2024 (the purchase date of the offering period). Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:27 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 500 | $8.60 | $4,300.00 |
DisclosureSEC source: 0000950170-24-068006 · ownership.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,734 Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:27 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 500 | $9.20 | $4,600.00 |
DisclosureSEC source: 0000950170-24-068006 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,234 Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 21:04 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 250 | $17.43 | $4,357.50 |
DisclosureSEC source: 0000950170-24-022050 · ownership.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,734 Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 21:04 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $17.38 | $17,380.00 |
DisclosureSEC source: 0000950170-24-022050 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,484 Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:49 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0000950170-24-002565 · ownership.xml · derivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning with the first anniversary of the grant date. Read SEC document |
| December 12, 2023 Filed Dec 12, 2023 21:37 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 950 | $12.45 | $11,827.50 |
DisclosureSEC source: 0000950170-23-069750 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,484 Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 00:06 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 500 | $10.68 | $5,340.00 |
DisclosureSEC source: 0000950170-23-067875 · ownership.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,534 Read SEC document |
| November 30, 2023 Filed Dec 5, 2023 00:06 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 1,034 | $9.06 | $9,369.07 |
DisclosureSEC source: 0000950170-23-067875 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,034 F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on July 1, 2023 and ending on November 30, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Company's stock on November 30, 2023 (the purchase date of the offering period). F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on July 1, 2023 and ending on November 30, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Company's stock on November 30, 2023 (the purchase date of the offering period). Read SEC document |
| November 21, 2023 Filed Nov 21, 2023 21:15 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $10.26 | $10,260.00 |
DisclosureSEC source: 0000950170-23-065502 · ownership.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| November 21, 2023 Filed Nov 21, 2023 21:15 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $10.30 | $10,300.00 |
DisclosureSEC source: 0000950170-23-065502 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Read SEC document |
| November 16, 2023 Filed Nov 16, 2023 19:38 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $12.15 | $12,150.00 |
DisclosureSEC source: 0000950170-23-064444 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Read SEC document |
| November 15, 2023 Filed Nov 15, 2023 21:31 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $13.25 | $13,250.00 |
DisclosureSEC source: 0000950170-23-064208 · ownership.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 19:38 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $12.45 | $12,450.00 |
DisclosureSEC source: 0000950170-23-064444 · ownership.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:31 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $12.88 | $12,880.00 |
DisclosureSEC source: 0000950170-23-064208 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| August 16, 2023 Filed Aug 16, 2023 21:57 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $17.06 | $17,060.00 |
DisclosureSEC source: 0000950170-23-043056 · ownership.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Read SEC document |
| August 16, 2023 Filed Aug 16, 2023 21:57 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $17.05 | $17,050.00 |
DisclosureSEC source: 0000950170-23-043056 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| August 15, 2023 Filed Aug 15, 2023 20:43 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $17.93 | $17,930.00 |
DisclosureSEC source: 0000950170-23-042840 · ownership.xml · nonDerivative · entry 5 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| August 15, 2023 Filed Aug 15, 2023 20:43 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $17.94 | $17,940.00 |
DisclosureSEC source: 0000950170-23-042840 · ownership.xml · nonDerivative · entry 4 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| August 15, 2023 Filed Aug 15, 2023 20:43 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $17.96 | $17,960.00 |
DisclosureSEC source: 0000950170-23-042840 · ownership.xml · nonDerivative · entry 3 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| August 15, 2023 Filed Aug 15, 2023 20:43 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $17.89 | $17,890.00 |
DisclosureSEC source: 0000950170-23-042840 · ownership.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| August 15, 2023 Filed Aug 15, 2023 20:43 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $17.92 | $17,920.00 |
DisclosureSEC source: 0000950170-23-042840 · ownership.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 22:50 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,000 | $16.15 | $16,150.00 |
DisclosureSEC source: 0001209191-23-038909 · doc4.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:25 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037870 · doc4.xml · derivative · entry 1 O'Toole David D · CIK 0001491140 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 13:57 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerStock Option (right to buy) · Derivative | 10,750 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001385508-23-000053 · wf-form4_167785181398452.xml · derivative · entry 7 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,750 shares Expires 2031-01-26 F5 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F5 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 13:57 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock · Derivative | 8,250 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001385508-23-000053 · wf-form4_167785181398452.xml · derivative · entry 6 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,250 shares Expires 2030-01-07 F5 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F5 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 13:57 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $13.61 | $0.00 |
DisclosureSEC source: 0001385508-23-000053 · wf-form4_167785181398452.xml · derivative · entry 5 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,000 shares Expires 2029-01-02 F5 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F5 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 13:57 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock | 2,000 | $20.00 | $40,000.00 |
DisclosureSEC source: 0001385508-23-000053 · wf-form4_167785181398452.xml · nonDerivative · entry 4 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · kind: Disposed of pursuant the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 13:57 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-23-000053 · wf-form4_167785181398452.xml · nonDerivative · entry 3 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F3 · kind: 2,000 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 13:57 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock | 11,736 | $20.00 | $234,720.00 |
DisclosureSEC source: 0001385508-23-000053 · wf-form4_167785181398452.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Disposed of pursuant to the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 11,736 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 13:57 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock | 22,512 | $20.00 | $450,240.00 |
DisclosureSEC source: 0001385508-23-000053 · wf-form4_167785181398452.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,736 F1 · kind: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:17 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 541 | $20.26 | $10,960.66 |
DisclosureSEC source: 0001385508-23-000030 · wf-form4_167519983426592.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,248 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.